Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. Article

authors

  • Crouch, Eric
  • Kraker, RT
  • Wallace, DK
  • Holmes, JM
  • Repka, MX
  • Collinge, JE
  • Bremer, DL
  • Gray, ME
  • Smith, HA
  • Steinkuller, PG
  • Writing Committee for Pediatric Eye Disease Investigator, Group.

publication date

  • 2020

published in

PubMed Central ID

  • pmc6865236

number of pages

  • 6

start page

  • 14

end page

  • 20

volume

  • 138

issue

  • 1